UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000013716
Receipt number R000016013
Scientific Title A study of infliximab administration method for tacrolimus-resistant active ulcerative colitis
Date of disclosure of the study information 2014/04/15
Last modified on 2015/03/06 15:57:44

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study of infliximab administration method for tacrolimus-resistant active ulcerative colitis

Acronym

A study of infliximab administration method for tacrolimus-resistant active ulcerative colitis

Scientific Title

A study of infliximab administration method for tacrolimus-resistant active ulcerative colitis

Scientific Title:Acronym

A study of infliximab administration method for tacrolimus-resistant active ulcerative colitis

Region

Japan


Condition

Condition

ulcerative colitis

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Aims to evaluate the efficacy of infliximab for tacrolimus- resistant active ulcerative colitis by comparing the switching method of administration

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

rate of mucosal healing

Key secondary outcomes

remission rate
improvement rate
steroid-sparing effect
safety


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

YES

Institution consideration


Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

After administrating tacrolimus and infliximab for 6 weeks,tacrolimus is tapered to 0mg.

Interventions/Control_2

Infliximab monotherapy

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients who have been diagnosed with ulcerative colitis based on the diagnostic criteria of the Japanese Ministry of Health, Labour and Welfare.
Tacrolimus-resistance
16 years of age and older at the time of registration.
Patients who have been signed informed consent document before entering this study.

Key exclusion criteria

Patients applied to the medically contraindicated of infliximab
Patients during pregnancy
Patients are taking concomitant any other biological therapies or cyclosporine
Patients are determined to be inappropriate for administration of infliximab by doctors

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Reiko Kunisaki

Organization

Yokohama City University Medical Center

Division name

IBD Center

Zip code


Address

4-57 Urafune-cho, Minami-ku, Yokohama City, 232-0024, Japan

TEL

045-261-5656

Email

kunisakireiko@gmail.com


Public contact

Name of contact person

1st name
Middle name
Last name Reiko Kunisaki

Organization

Yokohama City University Medical Center

Division name

IBD Center

Zip code


Address

4-57 Urafune-cho, Minami-ku, Yokohama City, 232-0024, Japan

TEL

045-261-5656

Homepage URL


Email

kunisakireiko@gmail.com


Sponsor or person

Institute

Yokohama City University Medical Center

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

横浜市立大学附属市民総合医療センター(神奈川県)


Other administrative information

Date of disclosure of the study information

2014 Year 04 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2014 Year 03 Month 31 Day

Date of IRB


Anticipated trial start date

2014 Year 04 Month 15 Day

Last follow-up date

2016 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 04 Month 15 Day

Last modified on

2015 Year 03 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016013


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name